Genmab — December 2019
-
Enig.
-
De er selv inde på det: This data will sensitize physicians and possibly lead to generation of guidelines for closer monitoring of IgG, use of IVIG and other precautions in patients on daratumumab. In our own institution, we anticipate the detection of HGGE and use of IVIG in these patients to increase substantially.
-
PS: Det med med indgivelse af immunglobulin var mit eget bud uden at kende til praksis i forbindelse med behandling med dara. Det var så ikke skudt helt ved siden af.
-
-
Other precations = Pas ikke dine syge børnebørn.
-
Jeps.
-
Solsen skylder os en juleøl.
-
GENMAB-KONKURRENTER MED POSITIVE STUDIEDATA FOR KRÆFTMIDDEL - GENT
06:34
Det amerikanske medicinalselskab Bristol-Myers Squibb og biotekselskabet Bluebird kan glæde sig over positive resultater i et nyt studie med et middel mod knoglemarvskræft.Det drejer sig om et fase 2-studie med lægemiddelkandidaten bb2121, og resultaterne har levet op til studiets formål, oplyser selskaberne i en meddelelse fredag aften.
Ifølge Bloomberg News viste studiet, at mere end 80 pct. af patienterne, der
-
-
-
God morgen.
-
Mohamad Mohty
@Mohty_EBMT
·
3 t
#ASH19 Sunday thoughts at the end of the day:- BITE antibodies are likely to dominate the field rapidly and can seriously challenge the currently available CAR-T cells...https://twitter.com/Mohty_EBMT/status/1203873850045407232
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind